Vaccine developer Moderna could slow COVID-19 trials to add at-risk minorities

Shares of Moderna, one of the few companies in the final stages of developing a safe and effective COVID-19 vaccine, closed down about 3.5%. The drug developer aims to recruit 30,000 healthy volunteers and said it expected enrollment in the late-stage study, which began in late-July, to be completed in September. A growing body of evidence has shown that long-standing health and social inequities have resulted in increased risk of infection and death from COVID-19 among communities of color.